8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

T.Brümmendorf; J.Guigay; R.Mesía; J.Trigo; U.Keilholz; C.Dittrich; A.Kerber; M.Picard; J.Vermorken

首页> 外文期刊>European Journal of Cancer Supplements >8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

【24h】

8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

机译：8517期I期来自一项开放标签，随机，对照的I / II期研究（ADVANTAGE），用于评估复发/转移性鳞状细胞癌患者中不同cilengitide方案与顺铂，5-FU和西妥昔单抗的组合头和脖子（SCCHN）

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
T.Brümmendorf; J.Guigay; R.Mesía; J.Trigo; U.Keilholz; C.Dittrich; A.Kerber; M.Picard; J.Vermorken;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na < ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [J] . Ruzsa A., Sen M., Evans M., Investigational new drugs. . 2014,第6期

机译：2期，开放标签，1：1随机对照试验，探讨EMD 1201081联合西妥昔单抗治疗第二线西妥昔单抗-初次复发或转移性头颈部鳞状细胞癌（R / M SCCHN）的患者的疗效）
2. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I/II ADVANTAGE trial (phase II part) [J] . VermorkenJ.B., PeyradeF., KraussJ., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第3期

机译：顺铂，5-氟尿嘧啶和西妥昔单抗（PFE）联合或不联合西仑吉肽治疗复发/转移性头颈部鳞状细胞癌：I / II期ADVANTAGE随机试验的结果（II期部分）
3. 97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) [J] . J.Bourhis, F.Rivera, R.Mesia, European Journal of Cancer Supplements . 2003,第5期

机译：97西妥昔单抗（C225）与顺铂或卡铂和5-氟尿嘧啶（5-FU）联合用于头颈部复发和/或转移性鳞状细胞癌（R＆M SCCHN）患者（pts）的I期研究
4. Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma [C] . Nestor Rigual, Ambujakshan Dildeep, Gal Shafirstein Conference on photonic therapeutics and diagnostics IX . 2013

机译：间质性光动力疗法联合西妥昔单抗治疗复发性头颈部鳞状细胞癌
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Cisplatin 5-fluorouracil and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) [O] . J. B. Vermorken, F. Peyrade, J. Krauss, -1

机译：顺铂5-氟尿嘧啶和西妥昔单抗（PFE）含或不含西仑吉肽在头颈部复发/转移性鳞状细胞癌中：I / II期ADVANTAGE随机试验的结果（II期部分）
7. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial) [O] . Georgios Tsakonas, Lena Specht, Claus Andrup Kristensen, 2020

机译：随机阶段II与西汀昔单抗与5-FU和顺铂或Carboplatin与Cetuximab一起研究。西妥昔单抗与紫杉醇和卡铂联合治疗头部和颈部复发或转移性鳞状细胞癌的患者（Cetmet试验）

8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

著录项

引文网络

相似文献

相关主题

期刊订阅